Stay updated on Remibrutinib Long-term Extension in Urticaria Clinical Trial
Sign up to get notified when there's something new on the Remibrutinib Long-term Extension in Urticaria Clinical Trial page.

Latest updates to the Remibrutinib Long-term Extension in Urticaria Clinical Trial page
- CheckyesterdayChange DetectedUpdated the ClinicalTrials.gov page’s displayed revision/version label from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be a backend version update and does not modify study content or user-facing features.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.5.0 has been added and v3.4.3 has been removed.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded new study locations across multiple countries (examples include Uskudar, Melikgazi, Karsiyaka, Karabaglar, Efeler, Buca, Atakum, Adapazari, Hajdu Bihar Megye, Hesse, Bavaria, Cundinamarca, and more) and removed numerous sites; total locations updated from 207 to 208.SummaryDifference2%

- Check73 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2, indicating a minor UI/version change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check80 days agoChange DetectedRevision label updated to v3.4.1, replacing the previous v3.4.0.SummaryDifference0.0%

Stay in the know with updates to Remibrutinib Long-term Extension in Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Remibrutinib Long-term Extension in Urticaria Clinical Trial page.